chevron_leftBack
As of 24 April 2025, Biomind Labs Inc. has a market cap of $56.51M USD, ranking #24011 globally and #4 in Uruguay. It ranks #2436 in the Healthcare sector, and #774 in the Biotechnology industry.
Key Stats
Market Cap
$56.51MUSD
78.26M CAD
Enterprise Value
$57.42MUSD
79.52M CAD
EBITDA (TTM)
-$394.32KUSD
-546.09K CAD
Net Income (TTM)
-$687.53KUSD
-952.15K CAD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Alejandro Antalich
open_in_new
Website
biomindlabs.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | 0% | -22% | 17% | -31% | -6.7% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BMND
Biomind Labs Inc
ISIN: CA0907021012
Shares Out.:
Shares Outstanding:
77.531M1
Shares Float:
46.682M2
|
0.3500 CAD | |
|
BMNDF
Biomind Labs Inc
ISIN: CA0907021012
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.7000 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Biomind Labs Inc.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson’s disease. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
